Це відео не доступне.
Перепрошуємо.
Quarterly intravenous eptinezumab prevents migraine
Вставка
- Опубліковано 17 сер 2024
- An intravenous formulation of a calcitonin gene-related peptide inhibitor monoclonal antibody showed efficacy for preventing chronic migraine headaches for 3 months in a dose-ranging, phase 3 trial with 1,072 patients.
Any side effects?